Javascript verkar inte påslaget? - Vissa delar av Lunds universitets webbplats fungerar inte optimalt utan javascript, kontrollera din webbläsares inställningar.
Du är här

Radioimmunotherapy using 131I-labeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas

  • Ola Lindén
  • Jan Tennvall
  • Eva Cavallin-Ståhl
  • Lennart Darte
  • Michael Garkavij
  • K J Lindner
  • Michael Ljungberg
  • Tomas G Ohlsson
  • Katarina Sjögreen Gleisner
  • Karin Wingårdh
  • Sven-Erik Strand
Publiceringsår: 1999
Språk: Engelska
Sidor: 3287-3291
Publikation/Tidskrift/Serie: Clinical Cancer Research
Volym: 5
Nummer: 10 Suppl
Dokumenttyp: Artikel i tidskrift
Förlag: American Association for Cancer Research

Abstract english

Experience in using rapidly internalizing antibodies, such as the anti-CD22 antibody, for radioimmunotherapy of B-cell lymphomas is still limited. The present study was conducted to assess the efficacy and toxicity of a 131I-labeled anti-CD22 monoclonal antibody (mAb), LL2, in patients with B-cell lymphomas failing first- or second-line chemotherapy. Eligible patients were required to have measurable disease, less than 25% B cells in unseparated bone marrow, and an uptake of 99mTc-labeled LL2Fab' in at least one lymphoma lesion on immunoscintigram. Eight of nine patients examined with immunoscintigraphy were unequivocally found to have an uptake, and therapy with 131I-labeled anti-CD22 [1330 MBq/m2 (36 mCi/m2)] preceded by 20 mg of naked anti-CD22 mAb was administered. Three patients achieved partial remission (duration, 12, 3, and 2 months), and one patient with progressive lymphoma showed stable disease for 17 months. Four patients exhibited progressive disease. The toxicity was hematological. Patients with subnormal counts of neutrophils or platelets before therapy seemed to be more at risk for hematological side effects. Radioimmunotherapy in patients with B-cell lymphomas using 131I-labeled mouse anti-CD22 can induce objective remission in patients with aggressive as well as indolent lymphomas who have failed prior chemotherapy.


  • Cancer and Oncology


  • ISSN: 1078-0432
Michael Ljungberg
E-post: michael [dot] ljungberg [at] med [dot] lu [dot] se


Medicinsk strålningsfysik, Lund

+46 46 17 35 65

+46 70 817 31 15

SUS Lund Kampradhuset 12-11

Barngatan 2:1, Lund



Medicinsk strålningsfysik, Lund



Medicinsk strålningsfysik, Lund



Nuclear Medicine Physics